{"id":"NCT01802385","sponsor":"University of Minnesota","briefTitle":"Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis","officialTitle":"Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-09","primaryCompletion":"2017-09","completion":"2017-09-27","firstPosted":"2013-03-01","resultsPosted":"2020-01-13","lastUpdate":"2020-06-09"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cryptococcal Meningitis","Fungal Meningitis"],"interventions":[{"type":"DRUG","name":"Sertraline","otherNames":["Zoloft","Lustral"]}],"arms":[{"label":"Placebo","type":"NO_INTERVENTION"},{"label":"Sertraline 400mg","type":"EXPERIMENTAL"}],"summary":"This is a phase III trial to determine whether adjunctive sertraline will lead to improved survival 18-week survival.\n\nThere was an initial phase I/II unmasked dose finding pharmacokinetic study of CSF concentrations in 172 persons conducted from August 2013 to August 2014. See NCT03002012.","primaryOutcome":{"measure":"Survival","timeFrame":"18 weeks","effectByArm":[{"arm":"Placebo","deltaMin":125,"sd":null},{"arm":"Sertraline 400mg","deltaMin":109,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":2,"countries":["Uganda"]},"refs":{"pmids":["26971081","22508310","26324276","31345462","39972326","38152404","36303432","33677986","32843994","31242860","30345376","30325463","30256903"],"seeAlso":["http://www.idi-makerere.com/","http://www.accordiafoundation.org"]},"adverseEventsSummary":{"seriousAny":{"events":121,"n":231},"commonTop":["Non-serious Adverse Events"]}}